Semaglutide 3 mg tablets and weight loss: clearing up the confusion

The misconception: that 3 mg semaglutide is the starting point for weight loss

It is an understandable mix-up. Rybelsus tablets (which contain semaglutide in 3 mg, 7 mg and 14 mg strengths) have been available in UK pharmacies for several years, and they look similar to the newer Wegovy tablets on a prescription label. But the licences are entirely separate. Rybelsus was developed and approved to help manage blood-sugar levels in adults with type 2 diabetes. It has never held a UK authorisation for weight management.

Wegovy tablets, approved by the MHRA in June 2026, use the same active molecule (semaglutide) co-formulated with a different absorption enhancer called SNAC. The titration schedule the MHRA approved for weight management is 1.5 mg, then 4 mg, then 9 mg, rising to the 25 mg maintenance dose, with at least a month at each level. There is no 3 mg rung on that ladder. A prescriber discussing how oral semaglutide doses work for weight loss will always start from this licensed schedule, not the Rybelsus steps.

If you have already been taking Rybelsus under a doctor's supervision for diabetes and you're now curious about its effect on weight, that is a different clinical conversation, one for your own GP or specialist, not a weight-management service.

What the Wegovy tablet schedule actually looks like

Wegovy tablets are taken once each morning, on an empty stomach, with a small amount of plain water, roughly 120 ml. You wait at least 30 minutes before eating, drinking anything else, or taking other oral medicines. The tablet is swallowed whole. This routine matters because the SNAC absorption mechanism is sensitive to food and competing liquids; the specific requirements for taking oral semaglutide correctly are worth understanding before you start.

Treatment begins at the 1.5 mg tablet, a dose designed to let your system settle before the therapeutic work begins. Titration to 4 mg, then 9 mg, then 25 mg follows at intervals directed by your prescriber, and you can read about how the 7 mg semaglutide step fits into weight loss treatment to understand the thinking behind gradual dose increases. That 25 mg maintenance dose is where the trial evidence sits: the OASIS 4 phase-3 trial (64 weeks, 307 adults with obesity or overweight plus at least one weight-related condition, no diabetes) recorded an average weight reduction of around 13.6% against roughly 2.4% on placebo. Among participants who stayed fully adherent throughout, the average reached about 17%. Those figures come from Novo Nordisk's UK approval announcement and the trial data reviewed by the MHRA.

One practical advantage worth noting: Wegovy tablets require no refrigeration. Unlike the injection pen, which lives in the fridge, the tablet sits at room temperature, genuinely easier to manage when you travel or simply prefer not to rearrange the kitchen. You can read more about how Wegovy tablets compare to the injection if that distinction matters to your decision.

Who the Wegovy tablet is licensed for, and what that means in practice

The MHRA licence covers adults with a BMI of 30 or above, or a BMI between 27 and 29.9 alongside at least one weight-related condition such as high blood pressure, raised cholesterol or prediabetes. These criteria apply alongside a reduced-calorie diet and increased physical activity, the tablet works in combination with lifestyle changes, not instead of them.

A few points that a prescriber will work through with you. Wegovy tablets are not recommended during pregnancy, while breastfeeding, or if you are actively trying to conceive. They are not licensed for anyone under 18. Certain medical histories (including a personal or family history of medullary thyroid carcinoma, a condition called MEN2, or previous pancreatitis) require careful clinical discussion before semaglutide of any kind is considered. Side effects are predominantly gastrointestinal: nausea, loose stools, indigestion and occasional vomiting, typically most noticeable at the start of treatment or after a dose step up. The questions our prescribers hear regularly include how long these effects tend to last, the honest answer is days to a couple of weeks for most people, though it varies.

If you're sitting with a browser full of tabs trying to work out whether this is the right medicine or the right dose, that feeling is familiar. A lot of people reach this point after months of weighing up options, and pages such as the one covering what the semaglutide 14 mg tablet involves can help clarify where each strength sits in the broader picture. The licensed oral semaglutide dose schedule for weight loss is set out clearly at the MHRA's published guidance, and the NHS medicines information for semaglutide at nhs.uk/medicines/semaglutide is a reliable place to read the patient-level detail. Worth checking both before you proceed.

The private route: clinical assessment, not a simple purchase

Wegovy tablets are a prescription-only medicine. The only legal route to them in the UK is a prescription following a proper clinical assessment, no pharmacy, online or otherwise, may supply them on request alone. At the time of writing, the NHS does not yet have a pathway for oral semaglutide; a NICE appraisal would be required before that changes.

For people exploring the private route, the cost structure is worth understanding before you commit. Some providers quote a headline figure that excludes the consultation, the prescription fee or the aftercare. There is a practical guide to where and how to get semaglutide tablets in the UK that covers what legitimate supply looks like. If you're comparing options, the overview of treatments at nume sets out what is included in a single transparent price.

Our prescribers (not software) read every consultation the same day it is submitted. If you're eligible and it is clinically appropriate, treatment is dispatched the same day for free next-working-day delivery. But the starting point is always the clinical conversation. Ready when you are: start your free consultation.